Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2-n-propylquinoline

Phytother Res. 2001 Nov;15(7):630-2. doi: 10.1002/ptr.877.

Abstract

It was reported previously that 2-n-propylquinoline was active against the epimastigote form of Trypanosoma cruzi. The effects of oral treatments with benznidazole and 2-n-propylquinoline were evaluated in Balb/c mice infected with T. cruzi chronically. The reference drug and 2-n-propylquinoline were administered 60 days post-infection for 30 days at 25 mg/mL. At 35 days post-treatment, the serological tests (ELISA) of the 2-n- propylquinoline-treated mice were significantly different from the controls (p = 0.01) and the benznidazole-treated mice (p = 0.03), while this was not the case at 85 days post-treatment. These results are encouraging for continuing the investigation of other analogues of 2-n-propylquinoline in experimental chronic Chagas' disease.

MeSH terms

  • Animals
  • Chagas Disease / drug therapy*
  • Chronic Disease
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Nitroimidazoles / therapeutic use
  • Phytotherapy*
  • Plant Extracts / therapeutic use
  • Quinolines / therapeutic use*
  • Rutaceae*
  • Trypanocidal Agents / therapeutic use*
  • Trypanosoma cruzi / immunology*
  • Trypanosoma cruzi / isolation & purification

Substances

  • 2-propylquinoline
  • Nitroimidazoles
  • Plant Extracts
  • Quinolines
  • Trypanocidal Agents
  • benzonidazole